Original Article
Nicotinamide nucleotide transhydrogenase acts as a new prognosis biomarker in hepatocellular carcinoma

Zhijiao Duan, Yang Song, Xuejing Zou, Shanshan Liu, Wanli Zhang, Li Liu

Hepatology Unit and Department of Infectious Disease, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

Received February 17, 2020; Accepted March 27, 2020; Epub May 1, 2020; Published May 15, 2020

Abstract: Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. Lipid metabolism is essential for cancer development. Nicotinamide nucleotide transhydrogenase (NNT) is abnormally expressed in multiple cancers; however, its role in HCC is unclear. We assessed the NNT expression level in The Cancer Genome Atlas (TCGA) cohort and Gene Expression Omnibus (GEO) datasets and found that the expression level of NNT was lower in HCC patients than non-cancer control subjects in the public databases. Survival analysis was conducted according to high and low NNT expression. Low NNT expression was significantly associated with a poor prognosis. For confirmation, the gene and protein expression of NNT in cancer and adjacent non-cancer tissues from HCC patients at our institute cohort indicated the lower expression level of NNT in cancer compared to adjacent non-cancer tissues using quantitative polymerase chain reaction and western blot, respectively. Bioinformatics was used to analyze the underlying mechanisms and establish the protein-protein interaction network of NNT. It showed that NNT is associated with functions of bile acid and fatty acid metabolism and their related genes. To conclude, our results supported that NNT expression is downregulated in HCC, and can serve as a novel prognostic biomarker.

Keywords: Hepatocellular carcinoma, nicotinamide nucleotide transhydrogenase, prognosis, lipid metabolism

Introduction

Hepatocellular carcinoma (HCC) ranks high with respect to incidence and mortality worldwide [1]. HCC is one of the leading causes of cancer-related mortality with more advanced disease cases and poor 5-year overall survival [2]. Despite common treatments of surgical resection, interventional therapy, and systemic pharmacological treatments such as targeted therapy, the survival time of patients with HCC remains poor [3-6]. Hepatitis, cirrhosis, and fatty liver are the main risk factors for HCC development [7]. Patients with chronic hepatitis B and C infection have a higher probability of developing HCC [8]. Fatty liver disease and diabetes are also major risk factor for HCC [9, 10]. Alpha-fetoprotein is a recognized marker of HCC; however, its prediction performance is not satisfactory [11]. Therefore, new markers, including prognostic predictors, and drug targets of HCC need to be discovered.

Deregulated cellular metabolism is one of the hallmarks of cancer [12]. Indeed, the majority of HCC patients show metabolic dysfunction. Lipid metabolism is an essential component of cancer metabolism [13]; lipids promote malignant biological behaviors such as tumor cell proliferation, invasion, and metastasis by regulating the fluidity of cell membranes and driving signal transduction cascades [14].

Recently, many studies have focused on understanding the mechanisms contributing to aberrant metabolic processes in cancer. Nicotinamide nucleotide transhydrogenase (NNT) is an antioxidative enzyme that converts nicotinamide adenine dinucleotide (NADH) to nicotinamide adenine dinucleotide phosphate (NADPH) [15, 16]. NADH and NADPH can be reduced in oxidative reactions in the cytosol and mitochondria during energy metabolism [17]. Accordingly, NNT plays a key role in redox
NNT acts as a prognosis marker in HCC

NNT acts as a prognosis marker in HCC
tional in several cancer types. For example, in
gastric cancer, NNT can regulate redox homeo-

\[\text{stasis to promote cancer growth and metasta-

\[\text{sis [19]. Moreover, NNT expression is upregu-

\[\text{lated in adrenocortical carcinoma, and trigger-

\[\text{ed anti-apoptosis pathways in cancer cells [20].

\[\text{NNT is also used as a sensor in mitochondrial

\[\text{biology [21]. The lack of NNT in macrophages

\[\text{was shown to exacerbate atherosclerosis in

\[\text{hypercholesterolemic mice [22]. The absence

\[\text{of NNT was also shown to inhibit cell prolifera-

\[\text{tion and aggressive behavior via alteration of

\[\text{hypoxia inducible factor-1 alpha- and histone

\[\text{deacetylase 1-dependent pathways [23]. How-

\[\text{ever, its role in HCC remains unclear.

Therefore, in the present study, we explored

\[\text{the expression profiles of NNT in HCC based on

\[\text{data from public databases and samples col-

\[\text{lected from patients at our institute, and de-

\[\text{termined their associations with survival. We

\[\text{further conducted bioinformatics analysis to

\[\text{identify the functions, and related genes and

\[\text{pathways of NNT. These results can provide

\[\text{new insight into the potential mechanisms con-

\[\text{tributing to HCC development, particularly with

\[\text{respect to the role of lipid metabolism, and

\[\text{highlight new targets for treatment.

Materials and methods

Clinical sample

Fresh HCC and paired adjusted tissues were

\[\text{collected at Nanfang Hospital, Southern Me-

\[\text{dical University (Guangzhou, China). Tissues

\[\text{were immediately frozen with liquid nitrogen

\[\text{after liver resection and stored in a refrigerator

\[\text{at -80°C for protein and RNA extraction. The

\[\text{study protocol was accepted by the Nanfang

\[\text{Hospital Institutional Review Board.

Expression data sets

HCC patients and health donors RNA-seq da-

\[\text{ta in The Cancer Genome atlas (TCGA) co-

\[\text{hort (https://tcga-data.nci.nih.gov/tcga/) were

\[\text{included in our study to explore the expressi-

\[\text{on of NNT. A set of array data (GSE20140,

\[\text{GSE14520 and GSE74656) were downloaded

\[\text{from the Gene Expression Omnibus (GEO)


Quantitative polymerase chain reaction

Total RNA was extracted from tissues using

\[\text{TRIzol reagent (TaKaRa Biotechnology, Dalian,

\[\text{China). Complementary DNA (cDNA) was syn-

\[\text{thesized by reverse transcription kit (TaKaRa

\[\text{Biotechnology, Dalian, China). Primer sequenc-

\[\text{es were synthesized as follows: NNT primer:

\[\text{Forward: CAGGTACCGGAGTGGAGTT, Reverse:

\[\text{TCCTTGAAGGCAAATCCTGTG; β-actin primer:

\[\text{Forward: GATTCCTATGTGGGCGACGA, Reverse:

\[\text{AGGTCTCAAACATGCTGGGT. Q-PCR was per-

\[\text{formed using the SYBR Green PCR kit (TaKaRa

\[\text{Biotechnology, Dalian, China), β-actin was cho-

\[\text{sen as an internal quantitative reference. Each

\[\text{experiment was conducted in triplicate.

Western blot

Tissues were lysed in radioimmunoprecipita-

\[\text{tion assay buffer (Cell Signaling Technology,

\[\text{Danvers, MA, USA) containing protease and

\[\text{phosphatase inhibitors (Roche, Basel, Switzer-

\[\text{land). Total Protein concentrations were mea-

\[\text{sured by the BCA protein assay kit (Thermo

\[\text{Fisher, Shanghai, China), Protein lysates were

\[\text{separated on a 10%-12% sodium dodecyl

\[\text{sulfate-polyacrylamide gel and electro-trans-

\[\text{ferred to a polyvinylidene difluoride membrane

\[\text{(Bio-Rad) that was blocked with 5% bovine

\[\text{serum albumin for 1 h at room temperature

\[\text{and probed overnight at 4°C with primary anti-

\[\text{bodies followed by incubation with horseradish

\[\text{peroxidase-conjugated secondary antibodies

\[\text{(Abcam, Cambridge, MA, USA). Immunodetec-

\[\text{tion was performed using enhanced chemilumi-

\[\text{nescence reagent (Pierce, Rockford, IL, USA).

\[\text{Antibodies against, NNT (1:1000, from Prote-

\[\text{intech, Chicago, IL, USA); β-actin (1:3000, from

\[\text{Abcam, Cambridge, MA, USA) were used.

GSEA

The GSEA program provided in broad institu-

\[\text{tute was used (http://www.broadinstitute.org/

\[\text{gsea/index.jsp). RNA-seq data from TCGA HCC

\[\text{cohort were analyzed. The data were split into

\[\text{NNT low or high group and were entered for

\[\text{GSEA program. The program was exploited to

\[\text{test whether numbers of a gene set or signa-

\[\text{tures were randomly distributed at the top or

\[\text{bottom of the ranking.

Statistical analysis

Data were analyzed using GraphPad Prism 5

\[\text{(GraphPad Prism Software Inc., San Diego,

\[\text{California) and expressed as mean ± SEM of

\[\text{at least three independent experiments. The}
NNT acts as a prognosis marker in HCC

Figure 1. NNT expression was downregulated in patients with hepatocellular carcinoma (HCC). A. The expression of NNT in the TCGA cohort was analyzed in a group of non-cancer donors and HCC patients (P < 0.0001). B. NNT expression level in patients with cirrhosis or HCC from the GSE20140 dataset (P < 0.01). C. Expression of NNT in liver non-cancer tissues and liver cancer tissues in the GSE14520 cohort (P < 0.01). D. NNT expression in para-carcinoma liver, liver cancer, and portal vein cancer thrombus tissue samples in the GSE74656 cohort.

Student’s t-test was used to assess the significance of differences between two groups.

All statistical tests were two-sided. P < 0.05 was considered statistically significant. Single, double and triple asterisks indicate statistical significances: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Results

NNT expression was downregulated in HCC tissues

Analysis of RNA-seq data from the TCGA cohort showed lower expression of NNT in the cancer group than in the non-cancer group (Figure 1A, P < 0.0001). Similarly, in the GSE-20140 dataset, patients with HCC had lower NNT expression levels than cirrhosis patients as the control group (Figure 1B, P < 0.01), and NNT levels were lower in the cancer group than those in the non-cancer group in the GSE14520 dataset (Figure 1C, P < 0.01). In the GSE74656 dataset, the expression level of NNT showed a gradual decline from the para-carcinoma liver tissues, liver tumor tissues, and portal vein tumor thrombus tissues (Figure 1D).

Low NNT expression was associated with a poor prognosis

The patients in the TCGA cohort were split into a high and low NNT expression group for survival analysis. Patients with high NNT expression showed significantly better overall survival (OS; Figure 2A, P = 0.0035) and disease-specific survival (DSS; Figure 2B, P = 0.032) than those in the low expression group. Among the 93 patients in the TCGA cohort with microvascular invasion of the cancer, those with high NNT expression also had a significantly better OS than patients with low NNT expression (Figure 2C, P = 0.025). Similarly, among the 30 patients in the TCGA cohort treated with sorafenib, a multitarget inhibitor, those with low NNT expression had a shorter OS than those with high NNT expression (Figure 2D).

NNT expression was downregulated in HCC tissues

Paired tissue samples collected from 12 patients with HCC at our institute were further evaluated for NNT expression. In line with the public data, NTT mRNA expression levels were significantly lower in the HCC tissues than in paired adjacent tissues (Figure 3A, P < 0.05). Western blot of 11 paired tissues further indicated reduced NNT protein expression in the
NNT acts as a prognosis marker in HCC

Figure 2. Low NNT expression was correlated with a poor prognosis. A. Overall survival (OS) analysis of hepatocellular carcinoma (HCC) patients in the TCGA cohort according to high and low NNT expression ($P = 0.0035$). B. Disease-specific survival (DSS) analysis of HCC patients in the TCGA cohort according to high and low NNT expression ($P = 0.032$). C. OS analysis of microvascular invasion-positive HCC patients with high and low NNT expression in the TCGA cohort ($P = 0.025$). D. OS analysis of patients treated with sorafenib with high and low NNT expression in the TCGA cohort.

Figure 3. NNT expression levels are reduced in cancer tissues in patients with hepatocellular carcinoma (HCC) at our institute. A. The mRNA expression of NNT in 12 HCC tissues and paired adjacent normal tissues measured using quantitative polymerase chain reaction ($P < 0.05$). B. The NNT protein level evaluated using western blot in 11 paired non-cancer and cancer tissues.

NNT is associated with lipid metabolism

Gene set enrichment analysis (GSEA) of the TCGA cohort demonstrated that the expression level of NNT was inversely correlated with gene signatures of bile acid metabolism.
NNT acts as a prognosis marker in HCC

Figure 4. NNT was associated with lipid metabolism. A. Gene set enrichment analysis (GSEA) results plotted to visualize the correlation between the expression of NNT and gene signatures of bile acid metabolism ($P < 0.0001$) in the TCGA cohort. B. GSEA results plotted to visualize the correlation between the expression of NNT and gene signatures of fatty acid metabolism ($P < 0.0001$) in the TCGA cohort.

Figure 5. Network analysis of NNT. The protein-protein interaction network of NNT is shown in Figure 5. A total of 11 proteins constituted a complex of associations in a multi-centered interaction network with interaction scores $>0.9$. All of these genes (NNT, NADK, NADK2, CD38, NADSYN1, NMNAT1, NMNAT2, NMNAT3, ENPP1, ENPP3, and NUDT12) were significant hub genes interacting with other genes in the interaction network.

Discussion

HCC is a prevalent malignant induced within an established background of chronic liver disease and cirrhosis after long latency [24]. Metabolic processes dysfunction, HCC in particular, is common in the pathogenesis of cancer [16]. NNT has been shown to be altered in several types of cancer, implicating a role of lipid metabolism in cancer development and progression. Despite the fact that metabolic
dysfunction is a known risk factor for HCC, the role of NNT in HCC has not been investigated.

Here, we demonstrate that NNT expression is downregulated in HCC patients compared to that in various controls from public databases. Moreover, patients with high NNT levels had a better prognosis than those with low NNT levels. We further confirmed these findings from public cohorts in our own cohort of HCC patients, in which NNT expression was reduced in HCC tissues compared to that in paired normal adjacent tissues at both the mRNA and protein levels. Bioinformatics analysis further indicated that NNT is associated with functions of bile acid metabolism and fatty acid metabolism. NNT was also correlated with a large number of metabolism-related genes. More detailed mechanisms of these interactions should be experimentally investigated in the future, which may highlight additional treatment targets and cancer mechanisms.

Although there are limitations of the present study, the results suggest the potential of NNT as a novel prognostic biomarker for HCC patients. However, more detailed investigations with larger samples are needed to fully elucidate the role of NNT in HCC.

Acknowledgements

The study was supported by the National Natural Science Foundation of China (Grant Nos. 81672756 and 81773008).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Li Liu, Hepatology Unit and Department of Infectious Disease, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Tel: +86-20-62787693; Fax: +86-20-62787093; E-mail: liuli@i.smu.edu.cn

References


NNT acts as a prognosis marker in HCC


